These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 15840593)

  • 1. Sepsis of a prosthetic joint and biological therapies.
    Fernández-Castro M; Andreu JL; Muñoz P; Silva L
    Rheumatology (Oxford); 2005 Aug; 44(8):1076-7; author reply 1075. PubMed ID: 15840593
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

  • 3. Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.
    Silburn S; McIvor E; McEntegart A; Wilson H
    Ann Rheum Dis; 2008 Apr; 67(4):575-6. PubMed ID: 18349168
    [No Abstract]   [Full Text] [Related]  

  • 4. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP; Laurindo I; Scheinberg MA
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract]   [Full Text] [Related]  

  • 5. Pericardial effusions on anti-TNF therapy for rheumatoid arthritis--a drug side effect or uncontrolled systemic disease?
    Edwards MH; Leak AM
    Rheumatology (Oxford); 2009 Mar; 48(3):316-7. PubMed ID: 19106166
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice.
    Neven N; Vis M; Voskuyl AE; Wolbink GJ; Nurmohamed MT; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2005 Apr; 64(4):645-6. PubMed ID: 15769924
    [No Abstract]   [Full Text] [Related]  

  • 7. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
    Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
    [No Abstract]   [Full Text] [Related]  

  • 8. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
    Rozin AP; Braun-Moscovici Y; Balbir-Gurman A
    Ann Pharmacother; 2008 Dec; 42(12):1912-3. PubMed ID: 19033477
    [No Abstract]   [Full Text] [Related]  

  • 11. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
    Ostör AJ; Chilvers ER; Somerville MF; Lim AY; Lane SE; Crisp AJ; Scott DG
    J Rheumatol; 2006 Mar; 33(3):622-8. PubMed ID: 16511933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculous peritonitis.
    Finlay DG; Szauter K; Raju GS; Snyder N
    Am J Gastroenterol; 2005 Jul; 100(7):1624-5. PubMed ID: 15984997
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serious lung disease in RA and TNF-blockade--is there a connection?].
    Turesson C; Jacobsson L; Saxne T; Geborek P
    Lakartidningen; 2006 Feb 1-7; 103(5):308; author reply 308-9. PubMed ID: 16512575
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 15. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis.
    Geraghty EM; Ristow B; Gordon SM; Aronowitz P
    Clin Infect Dis; 2007 May; 44(10):e82-4. PubMed ID: 17443458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab: additional safety data from an open label study.
    Daniel CL; Moreland LW
    J Rheumatol; 2002 Apr; 29(4):647-9. PubMed ID: 11950000
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab-induced SLE-like syndrome involving the lung and pleura.
    Diri E; Tello W; Ratnoff WD; Nugent K
    Lupus; 2007; 16(9):764-6. PubMed ID: 17728373
    [No Abstract]   [Full Text] [Related]  

  • 18. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare?
    Aslanidis S; Pyrpasopoulou A; Douma S; Petidis K
    Arthritis Rheum; 2008 Jan; 58(1):327-8. PubMed ID: 18163500
    [No Abstract]   [Full Text] [Related]  

  • 19. Cryptococcal meningitis in a patient treated with infliximab.
    Muñoz P; Giannella M; Valerio M; Soria T; Díaz F; Longo JL; Bouza E
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):443-6. PubMed ID: 17240111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
    Roos JC; Chilvers ER; Ostor AJ
    J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.